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AbstrAct
Ovarian cancer carries a significant mortality. Since symptoms tend to be 
minimal, the disease is often diagnosed when peritoneal metastases are already 
present. The standard of care in advanced ovarian cancer consists of platinum-based 
chemotherapy combined with cytoreductive surgery. Unfortunately, even after optimal 
cytoreduction and adjuvant chemotherapy, most patients with stage III disease will 
develop a recurrence. Intraperitoneal administration of chemotherapy is an alternative 
treatment for patients with localized disease. The pharmacological and physiochemical 
properties of melflufen, a peptidase potentiated alkylator, raised the hypothesis 
that this drug could be useful in ovarian cancer and particularily against peritoneal 
carcinomatosis. In this study the preclinical effects of melflufen were investigated in 
different ovarian cancer models. Melflufen was active against ovarian cancer cell lines, 
primary cultures of patient-derived ovarian cancer cells, and inhibited the growth 
of subcutaneous A2780 ovarian cancer xenografts alone and when combined with 
gemcitabine or liposomal doxorubicin when administered intravenously. In addition, 
an intra- and subperitoneal xenograft model showed activity of intraperitoneal 
administered melflufen for peritoneal carcinomatosis, with minimal side effects and 
modest systemic exposure. In conclusion, results from this study support further 
investigations of melflufen for the treatment of peritoneal carcinomatosis from 
ovarian cancer, both for intravenous and intraperitoneal administration. 
INtrODUctION
Ovarian cancer (OC) has the highest mortality rate of 
all gynecological malignancies in western countries [1, 2]. 
In contrast to other common solid cancers, it is mostly 
diagnosed at an advanced stage, due to a lack of clinical 
symptoms and effective screening methods [3]. Currently, 
optimal debulking surgery combined with intravenous (IV) 
carboplatin/cisplatin and paclitaxel-based chemotherapy 
is the standard of care for primary OC, but historically 
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melphalan has been an important therapeutic option [4, 5]. 
Approximately 70–80% of patients with OC will relapse 
after first-line chemotherapy, and the majority of them will 
eventually die of their chemotherapy-resistant disease [6]. 
Therefore, new and more efficacious drugs for treatment 
of ovarian canacer are needed. However, as this disease 
rarely spreads systemically and remains mostly confined 
to the peritoneal cavity, and given that intravenous (IV) 
chemotherapy usually does not effectively penetrate into 
peritoneal tumors, locoregional administration has been 
investigated [7, 8]. Administration of intraperitoneal 
chemotherapy (IPEC), whether or not under hyperthermic 
conditions ((H)IPEC), might offer a benefit for peritoneal 
metastases as compared to IV chemotherapy, since it 
allows to achieve higher drug concentrations in the 
peritoneal ﬂuid but less systemic toxicity [5, 8, 9]. 
Melﬂufen (melphalan ﬂufenamide, chemically 
described as melphalanyl-p-L–ﬂuorophenylalanine ethyl 
ester) is an optimized lipophilic and targeted derivative 
of melphalan, an alkylating agent used for the treatment 
of different cancers for over fifty years. The hydrolytic 
cleavage of melﬂufen into melphalan in the cancer 
cell is mediated by the action of aminopeptidases, like 
aminopeptidase N (APN) [10–12]. APN or CD13, is a 
transmembrane ectopeptidase which is overexpressed 
in several hematopoietic and solid malignancies 
including ovary-, breast-, lung-, and thyroid cancers [13]. 
Additionally, APN has been described as marker of a 
malignant phenotype and to regulate tumor cell invasion, 
differentiation, proliferation, and apoptosis, as well as 
angiogenesis [14–16]. Interestingly, tumor samples from 
OC patients showed ubiquitous expression of APN in 
tumor associated blood vessels that were common in 
serous or mucinous subtypes, but less often in clear cell 
epithelial subtype [17, 18]. Moreover, inhibition of APN 
was reported to suppress proliferative- and migratory 
abilities of OC cells [19]. A study by Surowiak et al. 
suggested that APN is expressed to a higher extent in 
tumor samples taken during primary surgery as compared 
to samples from interval debulking after neoadjuvant 
chemotherapy, indicating a decrease in APN expression 
after initial chemotherapy treatment [18].
Preclinical in vitro and in vivo models showed that 
melﬂufen exhibits significant antitumor activity in various 
cancers, superior to melphalan, as well as anti-angiogenic 
activity [13, 20–23]. Furthermore, melphalan has also 
been reported to be an efficacious alternative agent for 
patients undergoing cytoreductive surgery (CRS) and 
(H)IPEC, for aggressive and recurrent peritoneal surface 
malignancies [24, 25]. Since it is hypothesized that the 
lipophilicity of melﬂufen is balanced by its susceptibility 
to enzymatic hydrolysis, it is hypothesized that these 
properties make melﬂufen an ideal intraperitoneal (IP) 
agent for chemotherapy in OC patients. With this study, 
we want to investigate the effects of systemic as well 
as locoregional treatment with melﬂufen in preclinical 
models of OC.
rEsULts
cytotoxic activity in Oc cell lines and primary 
human tumor cells
Melﬂufen was active against OC cell lines A2780, 
A2780cis, ES-2, SK-OV-3 and SK-OV-3-Luc IP1 in vitro. 
The cytotoxic inhibitory concentration 50% (IC50) 
values were in the micromolar range (0.26–3.1 µM), and 
with a 5-32-fold superiority over melphalan (Table 1). 
Incubation of A2780 cells in hypoxic (1% O2) or anoxic 
(0.1% O2) environment reduced the activity of melﬂufen 
modestly, the IC50-value increased 1.2- and 2.0-fold 
respectively (not shown). For melphalan this effect was 
slightly more pronounced (2.0 and 2.6-fold, respectively) 
[26]. Melﬂufen in combination with carboplatin, 
doxorubicin, etoposide, gemcitabine, paclitaxel or the 
Poly-ADP (Adenosine Diphosphate)-Ribose Polymerase 
(PARP) III inhibitor DPQ, showed mainly additive effects, 
but also many antagonistic effects and some examples 
of synergistic events e.g. melﬂufen in combination with 
gemcitabine in a cisplatin resistant ovarian carcinoma 
cell line (A2780cis), and in combination with DPQ in 
ES-2. Doxorubicin combinations were usually additive. 
All tested combinations of melﬂufen and paclitaxel were 
antagonistic. A selection of melﬂufen combinations with 
gemcitabine, doxorubicin, DPQ and paclitaxel in A2780cis, 
A2780, SKOV-3 and ES-2 are shown in Figure 1. 
In primary cultures of patient-derived OC cells, 
the mean IC50–value for melﬂufen was 0.33 µM (95% CI 
of 0.27-0.39 µM) and for melphalan 16 µM (95% CI of 
12–20 µM), i.e. a 49-fold potency difference (Figure 2). 
No significant results were obtained for the analysis 
of stratification factors in the patient material (ascitic 
effusion, histological classification, prior chemotherapy, 
response to subsequent chemotherapy, patient survival 
after sampling, or stage of disease at sampling). 
Interestingly, samples obtained from patients treated with 
Pt containing chemotherapy in their most recent therapy 
responded as well to melﬂufen as samples from previously 
untreated patients (IC50–value post platinum = 0.24 and 
de novo = 0.27 µM). The cytotoxic activity (expressed 
as logIC50) of melﬂufen vs melphalan was significantly 
positively correlated (R2 = 0.42, p < 0.0001), as expected 
for two alkylating agents. Furthermore, the activity 
correlated fairly well for melﬂufen and other DNA-
interacting agents, i.e. vs cisplatin (R2 = 0.31, p < 0.0001), 
poorly but significantly vs doxorubicin (R2 = 0.17, 
p = 0.0006), but not vs docetaxel (R2 = 0.015, p = 0.42) or 
gemcitabine (R2 = 0.016, p = 0.58) (Figure 3).
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Melflufen IV shows in vivo activity in ovarian 
xenograft alone and combined with gemcitabine 
or liposomal doxorubicin
Comparing A2780 subcutaneous (SC) xenograft 
growth in untreated mice with those treated with single 
agent melﬂufen or melphalan (Figure 4A) showed that 
melﬂufen 8 mg/kg was significantly superior to the no 
treatment as well as to melphalan treatment with 4 mg/kg 
and 8 mg/kg (p = 0.0026). The effect of the combination of 
melﬂufen (4 mg/kg) with liposomal doxorubicin (2 mg/kg) 
was evaluated in the same A2780 ovarian carcinoma 
xenografts (Figure 4B). The combination offered better 
tumor control than either drug alone with almost no net 
tumor growth over the treatment period. The anti-tumor 
effect was significant (p = 0.0204), and multiparametric 
testing showed a significant difference between no 
treatment and the melﬂufen- liposomal doxorubicin 
combination. The effect of adding a sub-active dose of 
gemcitabine (i.e. 5 mg/kg, determined in a preparatory 
experiment) to melﬂufen 2, 4 or 8 mg/kg was also 
evaluated in A2780 xenografts (Figure 4C). Increased 
inhibition of growth of A2780 ovarian xenografts was 
evident after all melﬂufen doses with the highest dose 
Table 1: IC50-values and ratio of melphalan and melflufen in A2780, A2780cis, ES-2, SK-OV-3 
(obtained with FMCA), and SK-OV-3 Luc IP1 (obtained with MTT) with 95% confidence 
intervals in parenthesis
cell line Ic50 (µM) 
melflufen
Ic50 (µM) 
melphalan
Ic50 (µM) 
cisplatin
melphalan/
melflufen
A2780 0.26 (0.14–0.48) 1.4 (0.45–4.4) 1.1 (0.38–3.3) 5
A2780cis 1.3 (0.93–1.8) 19 (7.7–46) 7.6 (2.5–23) 15
ES-2 0.29 (0.21–0.41) 2.0 (0.90–4.5) 2.1 (1.4–3.3) 7.0
SK-OV-3 3.1 (2.1–4.7) > 100 52 (36–75) > 32
SK-OV-3-Luc IP1 0.89 (0.47–1.7) ND  12 (7.6–17) ND
ND = Not determined.
Figure 1: Melflufen combinations in different cell lines. Survival index of melﬂufen (2 µM) alone or in combination with 
gemcitabine (2 µM), doxorubicin (0.05 µM), DPQ (8 µM) or paclitaxel (0.013 µM) in A2780, A2780cis, SKOV-3, and ES-2 cell line. 
Mean of 3 replicates.
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approaching statistical significance (p = 0.0766). In a 
pilot experiment, the in vivo effect of melﬂufen was 
also evaluated in cisplatinum resistant A2780cis cells 
subcutaneously xenografted to female SCID mice. As 
expected, based on the observed in vitro cross resistance, 
neither melﬂufen (8 mg/kg) nor gemcitabine (5 mg/kg) 
had any significant effect on tumor growth. However, the 
combination of these two treatments resulted in delayed 
tumor growth and approximately doubled the time before 
reaching the endpoint, although with significant toxicity in 
the animals (not shown). 
In vivo activity of melflufen in IP and SP OC 
xenografts 
In the IP xenograft model (Figure 5), the volume of 
ascites present at sacrification was significantly lower in 
the cisplatin-treated versus untreated mice (p = 0.0190). 
Moreover, the simplified peritoneal carciomatosis 
index (sPCI) score (measured as the number of regions 
affected by tumor deposits) was significantly lower in the 
melﬂufen-treated versus untreated mice (p = 0.0476). A 
non-significant trend towards a lower bioluminiscence 
imaging (BLI) signal was observed for both treated groups 
(melﬂufen and cisplatin, p = 0.688 and p = 0.143). No 
significant treatment related weight change was observed 
(p = 0.759 and p = 0.813, melﬂufen and cisplatin vs 
untreated mice, respectively), however, there was a non-
significant trend for higher weight loss in the cisplatin 
treated animals. Also, 88% of the IP engrafted mice 
showed omental metastases. 
Mice treated with melﬂufen and cisplatin showed a 
similar, median survival of 44 and 46 days, respectively, 
almost doubling the median survival of 23 days for 
untreated mice (Figure 6). By conducting the log-rank 
test for trend, the increased survival was found significant 
for the treated animals (p = 0.0444 for melﬂufen). Two 
mice were censored (one from the melﬂufen and one 
from the cisplatin group), due to the injection of the drug 
in the colon instead of IP, which leads to bacteria in the 
abdominal cavity and consequently to sepsis. 
In the subperitoneal (SP) xenograft model 
(Figure 7), weight loss of the cisplatin treated animals was 
significantly higher compared to the melﬂufen-treated 
group (p = 0.0183). Significant antitumor activity was 
observed in both treated groups, with a lower sPCI score 
as compared to the untreated group (both treated groups = 
0.0022 vs control). Additionally, significant differences 
were demonstrated between the cisplatin-treated and 
untreated groups regarding tumor volume (p = 0.0376) 
and between the melﬂufen-treated and untreated group 
in terms of tumor weight (p = 0.0059). No significant 
differences were found regarding ascites score (p > 0.999) 
and BLI signal between the melﬂufen or cisplatin-treated 
and untreated mice, respectively (p = 0.372 and p = 0.175). 
Beside from the decreased weight loss there were no 
statistically significant differences between melﬂufen and 
the positive control cisplatin.
Rapid uptake of melflufen in the IP cavity
Parmacokinetic analysis of melﬂufen and its 
metabolites in IP ﬂuid or plasma in non-tumor bearing 
mice indicated that the peritoneal uptake of melﬂufen 
was extensive and rapid, as no remaining melﬂufen 
could be detected in IP ﬂuid already at 5 minutes after 
administration (Table 2). Melﬂufen was added in a 
concentration of 73.3 µg/ml (corresponding to 136 µM) 
into the IP cavity. The metabolites, des-ethylmelﬂufen 
(de-esterification), and melphalan (peptide cleavage) 
were detected in the IP ﬂuid at 5, 15 and 30 minutes at 
low concentrations (–8.8/9.7; 9.2/9.0; and 10/7.5 µM, 
respectively), corresponding to about 15% of the added 
dose. In plasma, only a small amount of melphalan could 
be detected (2.2 µM) at 30 minutes, and a very low 
concentration of des-ethylmelﬂufen (86 nM), which is 
consistent with the high esterase activity in rodent blood. 
DIscUssION 
Ovarian cancer (OC) carries a significant mortality, 
mainly related to a late disease stage at diagnosis [1–3]. 
Figure 2: Activity of melflufen and melphalan in patient-derived OC cells. The in vitro activity of melﬂufen (IC50= 0.33 µM) 
and melphalan (IC50 = 16 µM) in primary cultures of patient-derived OC cells (n = 82). Data are represented as mean ± SEM of 82 patient 
samples.
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Despite initial sensitivity to several lines of chemotherapy, 
in which platinum-taxane combinations play an important 
role, approximately two-thirds of patients eventually die 
from their disease. This illustrates the need for novel 
agents [6]. 
In this study, we demonstrate the in vitro 
cytotoxicity of melﬂufen against different OC cell lines 
and patient-derived OC cells, and show for the first time 
the in vivo antitumor efficacy of melﬂufen after IV or 
IP administration in different xenograft mouse models. 
The historical value of single agent melphalan in the 
treatment of OC is indisputable [4]. Melﬂufen, a lipophilic 
and targeted derivative of melphalan, is potentiated by 
the action of aminopeptidases such as APN, which is 
overexpressed or exhibits altered enzymatic activity in 
OC [11, 13, 27]. Melﬂufen showed a superior antitumor 
Table 2: Pharmacokinetic analysis of melflufen and its metabolites in IP fluid and in plasma, after 
IP injection
Time (minutes) Melflufen (µM) Des-ethyl-melflufen (µM) Melphalan (µM)
Dose (t = 0) 137 - -
5 IP ﬂuid - 8.4 (5.4–12) 5.5 (4.8–6.4)
15 IP ﬂuid - 8.8 (7.8–9.5) 5.1 (3.9–5.8)
30 IP ﬂuid - 9.5 (7.0–12) 5.8 (5.6–6.0)
30 plasma - 0.15 (0.082–0.22) 1.5 (1.3–1.8)
The lowest and highest values are in parenthesis.
Figure 3: The correlation of melflufen and other tested drugs in patient-derived OC cells. Melﬂufen vs. (A) melphalan 
(R2 = 0.42), (b) cisplatin (R2 = 0.31), (c) doxorubicin (R2 = 0.17), (D) docetaxel (R2 = 0.015) and (E) gemcitabine (R2 = 0.016), in primary 
cultures of patient-derived OC cells.
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Figure 4: Intravenous melflufen in ovarian carcinoma xenograft alone or in combination with liposomal doxorubicin or 
gemcitabine. Intravenous melﬂufen inhibits growth of ovarian carcinoma xenograft alone or in combination with liposomal doxorubicin 
or gemcitabine. Data shown are all mice (n = 4–5) at each time point, regardless if sacrificed or not. (A) Mean ± SEM of tumor size 
at indicated times post treatment with melﬂufen or melphalan (4 or 8 mg/kg). (b) Mean ± SEM of tumor size at indicated times post 
treatment with melﬂufen (4 mg/kg), also shown in (A) or liposomal doxorubicin (2 mg/kg) or their combination. (c) Mean ± SEM of tumor 
size at indicated time post treatment with gemcitabine (5 mg/kg) or gemcitabine (5 mg/kg) + melﬂufen (2, 4 or 8 mg/kg). 
Figure 5: IP model: in vivo effects of melflufen and cisplatin in SK-OV-3 Luc IP1 xenografts. Weight change during 
treatment (A); sPCI score (b); Ascites score (c); BLI signal, reported as relative value compared to the BLI signal at day 0 (D). (A, B and C) 
were measured when euthanized. Bars indicating median and interquartile range (n = 5 to 6 animals in each group).
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activity compared to melphalan in various in vitro and 
in vivo models of human cancer, including anti-angiogenic 
activity [13, 20–23]. The use of IP chemotherapy permits 
the administration of higher drug doses, while minimizing 
systemic toxicity [5, 8, 28–30]. Several large randomized 
trials have demonstrated that the addition of catheter-
based IP chemotherapy to adjuvant IV treatment results 
in a significantly better survival compared to IV treatment 
alone [31–33]. The above considerations prompted us to 
investigate the preclinical effects of melﬂufen in different 
OC xenograft models, with cisplatin as a positive control 
treatment, since the platinum compounds are considered 
the standard drug for IP and IV treatment of OC [30, 34]. 
Results of our in vitro experiments confirm the 
superior antitumor activity of melﬂufen compared to 
melphalan, showing a 5 to 32-fold higher activity for OC 
cell lines and a 43-fold higher activity for primary cultures 
of patient-derived OC cells. In addition, the antitumor 
effect of melﬂufen was also demonstrated in vivo in 
different xenograft models with A2780 cells xenografted 
SC and SK-OV-3 Luc IP1 cells xenografted IP and SP. 
Primary human tumor cells (PHTC) have received 
relatively little attention as a preclinical cancer stem 
cell like model [35]. In fact, in vitro response analysis 
of PHTC reports accurate diagnosis specific activity of 
cancer drugs and predict clinical response for individual 
patients [36, 37]. Furthermore, the in vivo selection of 
cells able to establish tumors in the used SK-OV-3 Luc 
IP model selects cells with ovarian cancer stem cell-like 
properties.
Systemically administered melﬂufen showed single 
agent activity in a subcutaneous A2780 xenografts model. 
Furthermore, additional in vitro and xenograft studies 
revealed an improved anti-tumor activity and tumor 
control, respectively, when melﬂufen was combined 
with either gemcitabine or liposomal doxorubicin, two 
agents used commonly used in OC [38, 39]. Previously, 
our group found synergistic activity of melﬂufen and the 
DNA-topoisomerase II inhibitor etoposide against several 
cell lines [40]. In addition, IP administered melﬂufen 
showed also antitumor efficacy in intraperitoneal (IP) and 
subperitoneal (SP) SK-OV-3 Luc IP1 xenografts, based on 
the sPCI scores. The IP model was set up to mimic diffuse 
ovarian cancer, while the SP model was chosen to induce 
isolated tumor nodules that we could follow in time. In 
general, mice tolerated melﬂufen treatment very well, and 
only modest weight changes were observed, as previously 
reported by Gullbo et al. [22]. In contrast, cisplatin 
treated and untreated mice lost weight, probably due to 
dehydration and cancer cachexia, respectively [41, 42]. 
Remarkably, 88% of the IP xenograft mice showed 
omental metastases, which might be explained by the 
important role of omental milky spots and splenoportal fat 
[43]. Furthermore, a trend towards a lower BLI for both 
xenograft models was found. However, BLI data could not 
be easily interpreted due to distinct variability in relatively 
small groups and to camouﬂage of the total ﬂux signal by 
the largest implant. 
A median survival of 44 and 46 days was found for 
melﬂufen and cisplatin, respectively, compared to a median 
of 23 days in the control group. Finally, pharmacokinetic 
analysis after IP administration of melﬂufen indicated 
a rapid and complete uptake from the abdominal cavity 
with undetectable concentrations already after 5 minutes. 
Figure 6: Kaplan-Meier survival curve of mice treated with melflufen and cisplatin. Mice treated with cisplatin and melﬂufen 
live longer than untreated mice, after IP injection of SK-OV3-Luc IP1 cells. Two mice (overlap) were censored because of death from non 
tumor-related causes and were indicated with a square (n = 5 to 6 animals in each group). 
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Concentrations of 2.2 µM melphalan were detected in 
mouse plasma after 30 minutes, a time point suggested 
to be relatively close to the Cmax. Interestingly, this is 
considerably lower than the melphalan Cmax of 50.3 µM 
after IP administration of the LD10 dose (71.3 mg/m²) [44]. 
This results suggest that the use of IP melﬂufen is safe 
and unlikely to yield mortality or significant hematologic 
toxicity. In contrast, systemically administered melﬂufen, 
given to patients with advanced or progressive ovarian 
carcinoma and non-small-cell lung cancer, caused 
reversible neutropeunia and thromocytopenia [27]. Paba-
Prada et al. found the same dose-limiting toxicities in 
relapsed - refractory multiple myeloma patients treated 
with melﬂufen and dexamethasone [45].
In conclusion, we show a significant activity of 
melﬂufen in vitro against OC cell lines and primary 
cultures of patient-derived OC cells. Melﬂufen activity is 
superior compared to that of the parental drug melphalan in 
subcutaneous as well as intra- or subperitoneal OC xenografts.
In addition, synergism was achieved with 
gemcitabine and liposomal doxorubucin, possibly 
indicating a potential for combination therapy of these in 
clinical trials for patients where conventional therapies 
have failed.
Figure 7: SP model: in vivo effects of melflufen and cisplatin in SK-OV-3 Luc IP1 xenografts. Weight change during 
treatment (A); sPCI score (b); Tumor volume (c); Tumor weight (D); Ascites score (E); BLI signal, reported as relative value compared 
to the BLI signal of day 0 (F); (A–E) were measured when euthanized. Bars indicating median and interquartile range (n = 5 to 6 animals 
in each group).
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MAtErIALs AND MEtHODs
Ethics statement
Patient sampling for the primary cultures of human 
tumor cells (PHTC) was approved by the regional ethical 
committee (Dnr 237/2007).
All animal experiments were approved by the 
Animal Ethics Committee of the Faculty of Medicine 
at Ghent University (ECD 14/66) or by the Animal 
Ethical committee in Stockholm Sweden (N 284/08 to 
Dr Spira), and were performed according to Belgian, 
Swedish and European legislature on animal welfare. 
Mice were examined daily for pain or discomfort and 
“The Guidelines for the welfare and use of animals in 
cancer research” were strictly followed for distention of 
the abdomen, physical condition and other clinical signs 
of mice, which show necessary intervention, as prescribed 
by The National Cancer Research Institute (NCRI)” [46]. 
Food and water was given ad libitum. All procedures were 
performed under general anesthesia (Forene®, AbbVie, 
Waver, Belgium) and analgesia (Ketoprofen, 5 mg/kg). 
reagents
The dipeptide melﬂufen, a kind gift from OncoPeptides 
AB, was dissolved in either dimethyl acetamide (DMA), 
dimetylsulfoxid (DMSO) or ethanol (EtOH) (Sigma-Aldrich, 
Diegem, Belgium or Stockholm, Sweden), stocked at –20°C 
and protected from light. Cisplatin Hospira was provided by 
Hospira Benelux BVBA (Antwerp, Belgium). Melphalan 
(Alkeran, GlaxoSmithKline, Mölndal, Sweden), gemcitabine 
(Gemzar, Lilly AB, Solna, Sweden), doxorubicin (Sigma-
Aldrich) and liposomal doxorubicin (Caelyx, Schering-
Plough, New Jersey, USA) were obtained from the State-
owned Pharmacy Chain (Apoteket AB, Uppsala, Sweden), 
and the PARP III inhibitor, DPQ, was obtained from Merck 
Millipore (Solna, Sweden). All chemicals which were not 
obtained as infusion solutions were dissolved in EtOH or 
DMSO and diluted in phosphate buffered saline (PBS) or 
saline. 
For the subcutaneous xenograft studies, melﬂufen 
or melphalan were dissolved in DMA and further 
diluted in 5% glucose infusion ﬂuid into indicated final 
concentrations less than 15 minutes prior to injection. 
Liposomal doxorubicin and gemcitabine were also diluted 
in 5% glucose infusion ﬂuid as described in Gallo et al. 
[47] to appropriate concentrations. 
For the IP experiments, cisplatin and melﬂufen 
(dissolved in DMSO/EtOH) were diluted in saline less 
than 15 minutes prior to injection. Isoﬂuran (Forene®), 
sevoﬂuran (Sevorane®, AbbVie) and 1 mg/ml ketoprofen 
(Rofenid®, Sanofi Aventis, Diegem, Belgium) were used 
for anesthesia and analgesia of the animals. Glucose 5% 
(0.2 ml; B Braun Medical N.V., Diegem, Belgium) and 
Hartmann’s solution (0.4 ml; B Braun Medical N.V.) were 
subcutaneously applied to hydrate all animals during 
treatment. Mice were IP injected with 0.2 ml (15 mg/ml) 
of D-luciferin (PerkinElmer, Zaventem, Belgium) 10 
minutes prior to BLI, which was analyzed with the Living 
Image® 4.3.1 software (IVIS® Lumina II, PerkinElmer). 
cell lines
The human OC cell lines, A2780 and A2780cis were 
obtained from Sigma Aldrich. The latter made resistant to 
cisplatin as previously described [48]. The ES-2 (CRL-
1978) and SK-OV-3 (HTB-77) cells were both purchased 
from American Type Culture Collection (ATCC, Wesel, 
Germany). The cells were cultured in RPMI 1640 (A2780 
and A2780cis) or McCoys 5A medium (ES-2 and SK-
OV-3) and complemented with 10% FCS and 2% pest/
glut (all Sigma Aldrich). The human OC cell line SK-OV-
3-Luc IP1 is a more potent, luciferase positive OC cell 
line, created through in vivo selection [49]. Sort Tandem 
Repeat (SRT) profiling was conducted as described 
by De Vlieghere et al. [49]. This cell line was cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Life technologies, ThermoFisher, Ghent, Belgium), 
supplemented with 2% penicillin/streptomycin (Life 
technologies) + 0.005% fungizone (Bristol-Myers-Squib 
B.V., Utrecht, The Netherlands) and 10% FCS (Sigma-
Aldrich) [50]. Saline and BD matrigel (Life Sciences, 
Antwerp, Belgium) were used to dilute SK-OV-3-Luc 
IP1 cells before IP and SP injection, respectively. The 
cell banks performed authentications by short tandem 
repeat analysis. All cell line experiments in Sweden were 
performed within 6 month after resuscitation, in Belgium 
STR was done to verify identity. 
Analyses of drug combinations 
Additive combination effect analysis was performed 
at concentrations of melﬂufen and standard drugs, 
producing a viability of 60–80% in single drug analysis. 
Firstly, single drug activity was determined in the cell 
lines to select suitable combination concentrations. A 
fixed concentration of melﬂufen (0.32, 0.16, or 0.08 µM 
for A2780 and ES-2 and or 4, 2, or 1 µM for A2780cis and 
SK-OV-3) and a seven step dilutions concentration range 
for the standard drug was added to the cells and analyzed 
by the FMCA. The effect of the combination was defined 
as synergistic if the observed viability was lesser than the 
sum of both drugs administered alone, i.e. the expected 
additive effect, and antagonistic if it was greater than the 
sum of both drugs administered alone.
Primary cultures of human tumor cells (PHTC) 
from patients
Ovarian cancer patient samples were obtained 
from 82 patients by either surgery or as needle biopsies, 
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and delivered to the laboratory within 24 hours. The cell 
preparation protocol described by Blom et al. was used 
[51]. Brieﬂy, the samples were minced and dispersed in 
collagenase (Collagenase type I, 1.5 mg/ml; Sigma and 
DNase Type I, 100 µg/ml; Sigma in CO2-Independent 
Medium; Gibco, pH 7.35 to 7.45) in 37°C for 1-4 
hours and purified by density gradient centrifugation 
(histopaque®-1077; Sigma Aldrich). Viability was 
determined by staining the cells with trypan or toluidine 
blue and counting in a Bürker chamber. A cytopathologist 
estimated the proportion of tumor cells by inspection of 
May–Grunwald–Giemsa-stained cytospin preparations. 
The cells were diluted in RPMI 1640 (complemented with 
10% FCS and 2% pest/glut) prior to seeding in culture 
plates for drug sensitivity testing. 
For analysis of different groups, the patient material 
was stratified for the factors ascitic effusion (yes/no), 
histological classification (high grade serous/low grade 
serous/others), prior chemotherapy (yes/no), response to 
subsequent chemotherapy (complete response vs. partial 
response/stable disease vs. progressive disease), patient 
survival after sampling (none vs. less than 2 year) and 
stage of disease at sampling (I–IIIC vs IV).
Viability assays (FMCA and MTT)
The Fluorometric cytotoxicity assay (FMCA) was 
used to assess the viability of OC cell lines and patient 
human tumor cells (PHTCs) as previous described 
elsewhere [52, 53]. Brieﬂy, the drugs and the cells were 
seeded (5000 cells/well for both cell lines and PHTCs) 
into a 384-well microtiter plate (Nunc) using an Echo 550 
liquid handler (Labcyte), and a pipetting robot Biomek 
2000 (Beckman Coulter), respectively. The plates were 
incubated for 72 hours in a 37°C humidified atmosphere 
containing 5% CO2 and were then washed with PBS once, 
and 10 µg/ml FDA (50 µl) was added. After 60 minutes 
of incubation, ﬂuorescence was measured (485/538 nm 
exitation/emission) in a Fluostar Omega ﬂuorometer 
(Biotech). The ﬂuorescence signal is directly proportional 
to the number of viable cells. Cell survival is presented as 
Survival Index% (SI%), defined as mean signal of each 
drug concentration divided by mean signal of the untreated 
cells (with blank signal subtracted). A concentration curve 
was made using Graph Pad Prism, and an IC50-value was 
calculated for each drug. Quality criteria for a successful 
assay included > 75% starting cell viability (by trypan or 
toluidine blue exclusion), a signal in untreated cells that 
were more than ten times the blank, and a coefficient 
of variation in untreated and blank wells of < 30%. 
Additionally, the effect of melﬂufen and melphalan was 
assessed in the A2780 cell line, cultivated in oxygen 
deprived environment (i.e. anoxia: 0.1% O2 or hypoxia: 
1.0% O2) employing a Ruskinn InVivo2 500 hypoxic 
incubator (Ruskinn Technology Ltd, Pencoed, UK) as 
previously described by Strese et al. [26]. 
In addition, prior to the IP in vivo experiments the 
traditional in vitro MTT ([3-4,5-Dimethylthiazolyl-2]-
2,5-Diphenyltetrazolium Bromide; (Sigma-Aldrich)) 
cell viability assay was carried out, to determine and to 
compare the sensitivity (IC50) of the SK-OV-3 LUC IP1 
cells to cisplatin. Brieﬂy, SK-OV-3 Luc IP1 cells were 
seeded as monolayers in 96-well plates at a density 
of 4.0 × 104 cells/ml. Subsequently, after 24 hours 
of incubation (37°C, 10% CO2), cells were exposed 
for 2 hours with cisplatin or melﬂufen at indicated 
concentrations (0.1-100 µM and 0.01-7 µM, respectively). 
After 72 hours of incubation, 20 µl MTT (5 mg/ml) was 
administered to each well for 2 hours. Subsequently, MTT 
solutions were removed and 100 µl of DMSO was added 
to each well to measure the absorbance of metabolically 
active cells. These measurements were performed at 570 
nm in a Paradigm Detection platform and analysed with the Soft 
Max Pro 6.1 software (BIO-RAD laboratories, Hemel 
Hempstead, United Kingdom). Three independent MTT 
assays, with three replicates were performed.
In vivo studies
Subcutaneous xenografts
For the subcutaneous (SC) xenografts studies, 
A2780 cells were engrafted into immunocompromized 
mice. Female SCID mice with a BALB c background 
(MTC Animal Facility, Karolinska Institutet, Stockholm, 
Sweden) aged of 8-10 weeks were used. To establish the 
xenografts, 1.0×106 A2780 cells were suspended in PBS 
and injected in a total volume of 0.2 ml subcutaneously 
in the right ﬂank of each mouse. The animals were either 
left untreated or treated with melﬂufen, melphalan, 
liposomal doxorubicin or gemcitabine as indicated below. 
Tumor growth was measured by caliper at indicated time 
points. Tumor size was calculated by the formula: Tumor 
size = [length × width²]/ 2 as described by Gallo et al. 
[47]. Detailed treatment schedule of the subcutaneous 
xenografts is given in Table 3. 
Intraperitoneal and subperitoneal xenografts
Athymic, nude-foxn1nu female mice (ENVIGO, 
NM Horst, the Netherlands) of 6 weeks age and an 
avarage weight of 20 g were conditioned one week before 
the start of each study. Two OC xenograft mice models 
with SK-OV-3 Luc IP1 cells were employed to study the 
antitumor efficacy of IP administered melﬂufen compared 
with treatment using saline and cisplatin, respectively. 
Engraftment was made with tumor cells injected IP 
(2.0 × 106 SK-OV-3 Luc IP1 cells, dissolved in 0.5 ml of 
saline) or bilateral in the SP space (between the muscle 
and the mesothelial layer of the peritoneal wall, 5.0 × 105 
of SK-OV-3 Luc IP1 cells dissolved in 50 µl BD matrigel 
(Life Sciences) [50, 54]. Mice (5-6/group) were treated 
Oncotarget59332www.impactjournals.com/oncotarget
Table 3: Treatment schedule of subcutaneous xenografts
Designation route Dose regimen
Vehicle IV - 2QW × 3W
Melﬂufen IV 4 mg/kg 2QW × 3W
Melﬂufen IV 8 mg/kg 2QW × 3W
Melphalan IV 4 mg/kg 2QW × 3W
Melphalan IV 8 mg/kg 2QW × 3W
Liposomal doxorubicin IV 2 mg/kg 1QW × 3W
Liposomal doxorubicin + melﬂufen IV + IV 2 mg/kg + 4 mg/kg 1QW × 3W + 2QW × 3W
Gemcitabine IP 5 mg/kg 2QW × 2W
Gemcitabine + melﬂufen IP + IV 5 mg/kg + 2 mg/kg 2QW × 2W
Gemcitabine + melﬂufen IP + IV 5 mg/kg + 4 mg/kg 2QW × 2W
Gemcitabine + melﬂufen IP + IV 5 mg/kg + 8 mg/kg 2QW × 2W
Table 4: Intraperitoneal treatment schedule of IP and SP xenografts
Xenograft model Drug Dose regimen
IP Saline - 3QW × 2W
IP Melﬂufen 4 mg/kg 3QW × 2W
IP Cisplatin 3 mg/kg 3QW × 2W
SP Saline - 3QW × 2W
SP Melﬂufen 4 mg/kg 3QW × 2W
SP Cisplatin 3 mg/kg 3QW × 2W
IP, 1 or 3 weeks after the injection of SK-OV-3 Luc 
IP1 cells in the IP and SP model, with either melﬂufen 
or cisplatin and monitored for another two weeks after 
treatment (Table 4). Untreated animals were injected 
with only saline. After each treatment mice were imaged 
using BLI and this signal was reported as relative values 
compared to the BLI signal at day 0. Furthermore, the 
physical condition of mice was followed-up during and 
after treatment. After 2 weeks of follow-up, mice were 
sacrificed and tumor nodules were harvested, weighted 
and measured. Additionally, tumor volumes (mm3) were 
estimated according to the formula mentioned above 
[47]. The sPCI score was based on the number of affected 
regions, because individual tumor nodules were too small 
and too numerous. However, this method is clinically used 
and described elsewhere [55, 56]. In addition, the used 
sPCI score was in agreement with Van Der Vange et al. 
[57]. 
Animals were euthanized when a body weight loss 
of 20% at any timepoint or 15% maintained for 72 h 
was observed compared with the pre-treatment weight 
or with the age-matched controls. In addition, a human 
endpoint was set on a BLI signal of 1.0 × 1011 photons/
second, considered to indicate maximal tumor growth. . 
When sacrificed, autopsies were done for all mice and the 
number of affected sPCI areas were determined [57]. 
In addition, a survival experiment was set-
up separately from the IP and SP tumor xenografts 
experiments. Therefore, the same IP model was used 
including treatment, imaging, and endpoints. 
Pharmacokinetic study 
A pharmacokinetic study was performed in 6 non-
tumor bearing animals treated once a week for 2 weeks 
(1QW × 2W) with either melﬂufen (n = 3) or with saline 
(n = 3). Intraperitoneal ﬂuid samples were drawn at 5, 
15, and 30 min each time after IP injection, while blood 
samples were only drawn once after 30 min. using cardiac 
puncture followed by euthanasia. After the IP addition of 
melﬂufen (73 µg/mL), the concentrations of melﬂufen, de-
ethyl melﬂufen and melphalan in plasma and IP ﬂuid were 
analyzed using HPLC-MS/MS at OnTarget Cemistry AB, 
Uppsala, Sweden. Quantification was performed using 
deuterium labeled internal standards (IS), D8-melﬂufen 
and D8-melphalan. 
statistical analysis
Statistical analysis was performed with Graphpad 
Prism™ 6 (Graphpad software, Inc.; La Jolla, Ca, USA). 
FMCA and MTT IC50-values were calculated using non-
linear regression analysis (dose-respons inhibition). 
Single comparisons of appropriate groups were done 
with Student’s t-test, multiple comparisons with one-way 
ANOVA and Turkey’s multiple comparison post -test. Data 
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from the in vivo IP and SP models were analyzed using 
non-parametric tests (Kruskall-Wallis and Dunn’s multiple 
comparisons test) and the Mann-Whitney test. Survival 
analysis was estimated using the Kaplan-Meier method, 
and survival differences between goups were evaluated 
using the log-rank test for trend. A p-value < 0.05 was 
considered to indicate statistical significance. 
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